| ￥3500 | |
| Z06362-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity |
> 90% as determined by BisTris PAGE > 90% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 51 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 85-110 kDa based on Bis-Tris PAGE result.. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Syndecan-1 hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC. »
Syndecan-1 hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Liver diseases such as liver cirrhosis, primary and metastatic liver cancers are still a major medical challenge. Syndecan-1 is one of the most important proteoglycans in the liver. Syndecan-1 is normally expressed on the surfaces of hepatocytes and cholangiocytes. Due to liver diseases the amount of syndecan-1 increases in the liver. |
| Synonyms | Syndecan-1; SYND1; CD138; SDC1; SDC; SDC1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
